Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), ...
An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...
hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive clinical trial results. The subcutaneous formulation allows self-administration, ...
BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...
Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...
Please provide your email address to receive an email when new articles are posted on . Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Subcutaneous and IV formulations of tocilizumab yielded similar rates of remission in patients with giant cell arteritis-associated aortitis, according to data published in Arthritis Care & Research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results